431 results
8-K
EX-99.1
SEEL
Seelos Therapeutics Inc
19 Mar 24
Other Events
4:05pm
neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. In ALS, both the upper motor neurons
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
will be responsible for underwriting discounts or commissions or agent’s commissions. The shares of Common Stock may be sold in one or more transactions at fixed … 2012 to 2013. At SunTrust Robinson Humphrey, he was responsible for coverage of small and mid-cap biotechnology companies with an emphasis on companies
8-K
EX-10.1
07gkg4m34tm7h vp
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.1
ndfcks ua
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.2
v920b80cu9rvh3ee18f
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
424B5
qg9bp
30 Jan 24
Prospectus supplement for primary offering
6:05am
UPLOAD
mua1i5kw24til8
21 Dec 23
Letter from SEC
12:00am
8-K
EX-4.2
mbc4xtxdm kfe
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-4.1
b6d 15kic73d7i
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-1.1
a1pivmnp
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
424B5
a8h39mswrzmb08r
30 Nov 23
Prospectus supplement for primary offering
4:58pm